[1]陶河清,综述,丁士刚*审校.双肾上腺素样激酶1在结直肠恶性肿瘤发病中的研究进展[J].中国微创外科杂志,2018,18(9):846-848.
点击复制

双肾上腺素样激酶1在结直肠恶性肿瘤发病中的研究进展()
分享到:

《中国微创外科杂志》[ISSN:1009-6604/CN:11-4526/R]

卷:
18
期数:
2018年9期
页码:
846-848
栏目:
文献综述
出版日期:
2018-12-06

文章信息/Info

作者:
陶河清综述丁士刚*审校
北京大学第三医院消化科,北京100191
文献标志码:
A

参考文献/References:

[1]Fu X,Brown KJ,Yap CC,et al.Doublecortin (Dcx) family proteins regulate filamentous actin structure in developing neurons.J Neurosci,2013,33(2):709-721.
[2]Patel O,Dai W,Mentzel M,et al.Biochemical and structural insights into doublecortin-like kinase domain 1.Structure,2016,24(9):1550-1561.
[3]Chandrakesan P,May R,Qu D,et al.Dclk1+ small intestinal epithelial tuft cells display the hallmarks of quiescence and self-renewal.Oncotarget,2015,6(31):30876-30886.
[4]Westphalen CB,Asfaha S,Hayakawa Y,et al.Long-lived intestinal tuft cells serve as colon cancer-initiating cells.J Clin Invest,2014,124(3):1283-1295.
[5]Nakanishi Y,Seno H,Fukuoka A,et al.Dclk1 distinguishes between tumor and normal stem cells in the intestine.Nat Genet,2013,45(1):98-103.
[6]Hirata Y,Sezaki T,Hagiwara T,et al.Su2004 enhanced expression of doublecortin-like kinase 1 (DCLK1) in the background mucosa of colon cancer.Gastroenterology,2015,148(4 Suppl 1): S-572.
[7]Sakaguchi M,Hisamori S,Oshima N,et al.miR-137 regulates the tumorigenicity of colon cancer stem cells through the inhibition of DCLK1.Mol Cancer Res,2016,14(4):354-362.
[8]Chandrakesan P,Yao J,Qu D,et al.Dclk1,a tumor stem cell marker,regulates pro-survival signaling and self-renewal of intestinal tumor cells.Mol Cancer,2017,16(1):30.
[9]Kantara C,O’Connell M,Sarkar S,et al.Curcumin promotes autophagic survival of a subset of colon cancer stem cells,which are ablated by DCLK1-siRNA.Cancer Res,2014,74(9):2487-2498.
[10]Vedeld HM,Skotheim RI,Lothe RA,et al.The recently suggested intestinal cancer stem cell marker DCLK1 is an epigenetic biomarker for colorectal cancer.Epigenetics,2014,9(3):346-350.
[11]Gagliardi G,Goswami M,Passera R,et al.DCLK1 immunoreactivity in colorectal neoplasia.Clin Exp Gastroenterol,2012,5:35-42.
[12]O’Connell MR,Sarkar S,Luthra GK,et al.Epigenetic changes and alternate promoter usage by human colon cancers for expressing DCLK1-isoforms: Clinical Implications.Sci Rep,2015,5:14983.
[13]O’Connell MR SS,Ward D,et al.Short (S) isoform of cancer-stem-cell marker,DCLK1,is critically required for maintaining proliferative/tumorigenic potential of human colon cancer cells (hCCCs) independent of DCLK1-L isoform.Gastroenterology,2016,150:S605.
[14]Hyekyung E,Hwang SY,Lee K,et al.Altered expression and localization of DCLK1 isoforms in gastric carcinogenesis.Gastroenterology,2015,148(4):S-565.
[15]Li K,Guo Q,Yang J,et al.FOXD3 is a tumor suppressor of colon cancer by inhibiting EGFR-Ras-Raf-MEK-ERK signal pathway.Oncotarget,2017,8(3):5048-5056.
[16]Sarkar S,O’Connell MR,Okugawa Y,et al.FOXD3 regulates CSC marker,DCLK1-S,and invasive potential:prognostic implications in colon cancer.Mol Cancer Res,2017,15(12):1678-1691.
[17]Mirzaei A,Tavoosidana G,Rad AA,et al.A new insight into cancer stem cell markers: Could local and circulating cancer stem cell markers correlate in colorectal cancer?Tumour Biol,2016,37(2):2405-2414.
[18]Gao T,Wang M,Xu L,et al.DCLK1 is up-regulated and associated with metastasis and prognosis in colorectal cancer.J Cancer Res Clin Oncol,2016,142(10):2131-2140.
[19]乐安君,朱海杭,俞文秀,等.DCLKl在结直肠癌、结直肠腺瘤中的表达及临床研究.中国医师杂志,2016,18(3):406-409.
[20]Mirzaei A,Madjd Z,Kadijani AA,et al.Evaluation of circulating cellular DCLK1 protein,as the most promising colorectal cancer stem cell marker,using immunoassay based methods.Cancer Biomark,2016,17(3):301-311.
[21]王敏,徐伶玲,蒋玉良,等.结直肠癌患者血浆中DCLK1的表达及意义.肿瘤,2015,35(5):572-578.

备注/Memo

备注/Memo:
*通讯作者,E-mail:dingshigang222@163.com
更新日期/Last Update: 2018-12-06